Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
Eur J Cancer. 2004 Feb;40(3):403-10.
Eur J Cancer. 2004.
PMID: 14746859
Clinical Trial.
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ.
Gralla RJ, et al. Among authors: guoguang ma j.
Cancer. 2005 Aug 15;104(4):864-8. doi: 10.1002/cncr.21222.
Cancer. 2005.
PMID: 15973669
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite